22384-44-7

Upstream product

• 7459-46-3 triethyl 1,1,2-ethanetricarboxylate 
• 57-13-6 urea 

Downstream Products

• 889944-72-3 ethyl 2-(2,4,6-trichloropyrimidin-5-yl)acetate 
• 1312162-29-0 2-(2-(2-methoxy-4-morpholinophenylamino)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-methylbenzamide 
• 1312162-73-4 2,4-dichloro-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine 
• 1312163-37-3 4-chloro-N-(2-methoxy-4-morpholinophenyl)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolO[2,3-d]pyrimidin-2-amine 
• 1312163-38-4 2-(2-(2-methoxy-4-morpholinophenylamino)-7-(4-methoxybenzyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-N-methylbenzamide 

Relevant academic research and scientific papers

AROMATIC COMPOUNDS FOR USE IN ACTIVATING HEMATOPOIETIC STEM AND PROGENITOR CELLS

Disclosed herein are new aromatic compounds, compositions that include one or more aromatic compounds, and methods of synthesizing the same. Also disclosed herein are methods of increasing and/or expanding cells, including stem cells, hematopoietic stem cells, progenitor cells, and placenta or cord blood-derived cells, with one or more compounds or compositions described herein. Also disclosed herein are methods of increasing and/or expanding differentiated hematopoietic cells with one or more compounds or compositions described herein.

COMPOUNDS FOR IMPROVING MRNA SPLICING

Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.